CardioVascular BioTherapeutics (OTCBB:CVBT)

Dear Readers:

For companies that have created potentially life-changing, breakthrough technologies in the health care space accolades from major publications like Business Week are welcome vehicles in the pathway to exposure and understanding.  It’s an entirely different event when your peer group- pharmaceutical executives- calls your angiogenesis therapy ‘one of the seven top therapies and technologies vying to deliver the next decade's breakthroughs and blockbusters. 

A recent Pharmaceutical Executive magazine article profiles new technologies that have made it possible to treat disease in unprecedented ways and highlights CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) development of protein-based angiogenesis as part of a group of therapies that ‘form a vision for the next generation of drugs.  Angiogenesis refers to the growth of new blood vessels that may help those suffering from coronary heart disease by increasing blood flow associated with the disease.

     

**Breaking News** Released This Morning

Press Release Source: CardioVascular BioTherapeutics, Inc.
Tuesday August 14, 8:00 am ET

LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT - News) today announced that Pharmaceutical Executive magazine has named CVBT's angiogenesis therapy as "one of the seven top therapies and technologies vying to deliver the next decade's breakthroughs and blockbusters," in its August 2007 issue. Pharmaceutical Executive is an award-winning, highly respected global business and marketing magazine for pharmaceutical executives. Angiogenesis refers to the growth of new blood vessels that may help those suffering from coronary heart disease by increasing blood flow associated with the disease. The article, titled "Tomorrow's Drugs," can be viewed at www.cvbt.com.

The Pharmaceutical Executive article profiles new technologies that have made it possible to treat disease in unprecedented ways and highlights CVBT's development of protein-based angiogenesis as part of a group of therapies that "form a vision for the next generation of drugs." The feature further states that this next generation of drugs "will transform the industry and the face of healthcare in the decades to come."

"We are thrilled to be recognized by Pharmaceutical Executive magazine for our work in the field of angiogenesis therapy," said Dan Montano, CEO, CVBT. "Recognition of our therapy and technology as a potential breakthrough treatment for cardiovascular disease in this article and in BusinessWeek Online's recent article titled 'The Search for Angiogenesis,' is truly an honor and highlights the need for next-generation therapies. We look forward to bringing to market a viable treatment that will help heart disease patients return to the quality of life they once knew."

CVBT will begin its Phase II clinical trial of its drug candidate, CVBT-141H, in September/October of this year in patients with severe coronary heart disease.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates formulated with human Fibroblast Growth Factor-1 (FGF-1) to treat a number of diseases characterized by inadequate blood flow to a tissue or organ. The Phase II trial to treat severe coronary heart disease has been approved by the FDA and dosing is planned to begin in the fall of this year. Additionally, CVBT is close to completion of a Phase I clinical trial for dermal diabetic and venous ulcer healing, where its drug candidate CVBT-141B was applied topically. CVBT also has initiated a Phase I clinical trial using a third drug candidate, CVBT-141C, in patients with Peripheral Arterial Disease.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Contact:

Schwartz Communications
Nicki Polatin, 415-512-0770
Erin Walsh, 781-684-0770
cvbt@schwartz-pr.com

Source: CardioVascular BioTherapeutics, Inc.
>>>Spacer>>>
 
 

About CardioVascular BioTherapeutics

Cardiovascular disease is the underlying cause of 36.3%, or one of every 2.8 deaths in the United States.  
Nearly 2,400 Americans die of cardiovascular disease each day, an average of one death every 36 seconds.¹

CardioVascular BioTherapeutics, Inc. (OTC/BB: CVBT) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide leading cause of death. The Company is developing injectable and topical formulations of its active pharmacological ingredient (API) to facilitate the growth of new blood vessels (angiogenesis) in the heart, tissues and organs that have been compromised by impaired blood supply (hypoxia, ischemia). The Company’s API contains FGF-1141 a human protein manufactured using a proprietary technology.  FGF-1 stimulates the growth and proliferation of the three main cell types of blood vessels; endothelial cells, smooth muscles cells and pericytes.

CVBT-141A, the Company’s lead drug candidate successfully completed initial clinical trials in Germany during the 1990s, with no drug-related adverse events and a statistically significant increase in localized blood vessel growth (and perfusion) both in patients also receiving coronary by-pass procedures and in patients with severe coronary heat disease (CHD) receiving CVBT-141A, as the sole therapy. Enrollment and treatment has been completed in an FDA authorized Phase I study with CVBT-141A, administered via injection in severe CHD patients. The protocol design for the Phase II trial is underway, with FDA input, and is planned to initiate in 2007.

CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of FGF-1141 aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral artery disease, and pledges to continue exploration for additional applications of FGF-1. 
>>>Spacer>>>

Other Recent News from CVBT)

LAS VEGAS--(July 11, 2007)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) announced today that the U.S. Food and Drug Administration (FDA) has authorized the company's Phase II Clinical Protocol for its protein drug candidate, human fibroblast growth factor-1 (FGF-1), for the treatment of severe coronary heart disease.

The Phase II Clinical Protocol incorporates injection catheter delivery of FGF-1. The company plans to commence the international study at 30 medical centers in the U.S., Canada and Europe. It will work with Biologics Delivery Systems Group, Cordis Corporation, a worldwide leader in developing and manufacturing innovative technologies for interventional cardiologists, to identify clinical sites with expertise in utilizing the advanced NOGA® XP Cardiac Mapping System and the MyoStar(TM) Injection Catheter. The use of a catheter to deliver CVBT's drug candidate permits the examination of a placebo control group in this Phase II trial, which was not possible when the drug was surgically administered in the Phase I study.

a

To Contact CVBT

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.
 

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP has been paid nineteen thousand two hundred dollars by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period.. Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.